KEYNOTE-055 support the safety, tolerability and anti-tumour activity of pembrolizumab as a monotherapy in patients with HNSCC with disease progression on platinum-based and cetuximab (EGFR mAb) therapy [441]. The gene discussed is EGFR; the disease is neoplasm.